Патогенез ВИЧ-инфекции: 25 лет открытий и загадок ... - Tb-hiv.ru

154 AIDS, ðóññêîå èçäàíèå, 2009, òîì 2, N¹ 2 A. Carr, J. AminBristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline,Merck и Roche; спонсорские пожертвования на проведениелекций от компаний Abbott, Boehringer-Ingelheim,Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline,Merck и Roche; а также являлся членом консультативногосовета компаний Abbott, Bristol-Myers Squibb,Gilead Sciences, GlaxoSmithKline, Merck и Roche.Janaki Amin заявляет об отсутствии конфликта интересов.Австралийский национальный центр эпидемиологииВИЧ и клинических исследований (NationalCentre in HIV Epidemiology and Clinical Research) существуетпри поддержке Австралийского департаментаздравоохранения и проблем старения (CommonwealthDepartment of Health and Aging). Andrew Carr получалстипендию, предоставленную Австралийским советомпо исследованиям в области медицины и здравоохранения(Australian National Health and Medical ResearchCouncil).Ëèòåðàòóðà1. World Health Organization. 2006 Antiretroviral therapy for HIVinfection in adults and adolescents: recommendations for a publichealth approach — 2006 revision. Accessed on 5 July 2008. http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf.2. Panel on Antiretroviral Guidelines for Adult and Adolescents, Departmentof Health and Human Services. 29 January 2008. Guidelinesfor the use of antiretroviral agents in HIV-infected adults andadolescents. Accessed on 5 July 2008. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.3. Hammer SM, Saag MS, Schechter M, et al., International AIDS Society— USA panel. Treatment for adult HIV infection: recommendationsof the International AIDS Society — USA Panel. JAMA 2006;296:827–843.4. Gazzard B, Bernard AJ, Boffito M, et al., Writing Committee, BritishHIV Association. British HIV Association (BHIVA) guidelines forthe treatment of HIV-infected adults with antiretroviral therapy. HIVMed 2006; 7:487–503.5. European AIDS Clinical Society. Guidelines for the clinical managementand treatment of HIV-infected adults in Europe. Accessed on 5July 2008. http://www.eacs.eu/guide/index.htm.6. Yazdanpanah Y, Sissoko D, Egger M, et al. Clinical efficacy of antiretroviralcombination therapy based on protease inhibitors or nonnucleosideanalogue reverse transcriptase inhibitors: indirect comparisonof controlled trials. BMJ 2004; 328:249–255; doi: 10.1136/bmj.37995.435787.A6.7. Chou R, Fu R, Huffman LH, Korthuis PT. Initial highly-active antiretroviraltherapy with a protease inhibitor versus a non-nucleosidereverse transcriptase inhibitor: discrepancies between direct and indirectmeta-analyses. Lancet 2006; 368:1503–1515.8. Bartlett JA, Fath MJ, DeMasi R, et al. An updated, systematic overviewof triple combination therapy in antiretroviral-naive, HIV-infectedadults. AIDS 2006; 20:2051–2064.9. May M, Sterne JA, Sabin C, et al., Antiretroviral Therapy CohortCollaboration. Antiretroviral Therapy (ART) Cohort Collaboration.Prognosis of HIV-1-infected patients up to 5 years after initiation ofHAART: collaborative analysis of prospective studies. AIDS 2007;21:1185–1197.10. Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy forHIV infection: a controlled, randomised study in antiretroviral-naiveHIV-1-infected patients. Antiviral Ther 2003; 8:339–346.11. Maggiolo F, Migliorino M, Maserati R, et al., Once Study Group.Virological and immunological responses to a once-a-day antiretroviralregimen with didanosine, lamivudine and efavirenz. AntiviralTher 2002; 6:249–253.12. U.S. Department of Health and Human Services Food and DrugAdministration Center for Drug Evaluation and Research (CDER).Guidance for industry. Antiretroviral drugs using plasma HIV RNAmeasurements: clinical considerations for accelerated and traditionalapproval. Accessed on 5 July 2008. http://www.fda.gov/cder/guidance/3647fnl.pdf.13. Building models stepwise. In: Practical statistics for medical research.Altman DG, Chapman and Hall, London; 1991. pp. 340–351.14. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing withpublication and other biases in meta-analysis. BMJ 2001; 323:101–105.15. Mocroft A, Ledergerber B, Zilmer K, et al., EuroSIDA study group andthe Swiss HIV Cohort Study. Short-term clinical disease progressionin HIV-1-positive patients taking combination antiretroviral therapy:the EuroSIDA risk-score. AIDS 2007; 21:1867–1875.16. Lactic Acidosis International Study Group. Risk factors for lactic acidosisand severe hyperlactataemia in HIV-1-infected adults exposedto antiretroviral therapy. AIDS 2007; 21:2455–2464.17. Berenguer J, Gonzalez J, Ribera E, et al. Didanosine, lamivudine andefavirenz vs zidovudine and efavirenz, for initial treatment of HIVinfection over 48 weeks: a randomised, noninferiority clinical trial,GESIDA. In: Abstracts of the 46th International Conference on AntimicrobialAgents and Chemotherapy, Chicago, USA, September,2007, Abstract 383.18. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet2000; 356:1423–1430.19. Friis-Moller N, Sabin CA, Weber R, et al., Data Collection on AdverseEvents of Anti-HIV Drugs (DAD) Study Group. Combinationantiretroviral therapy and the risk of myocardial infarction. N Engl JMed 2003; 349:1993–2003.20. Strategies for Management of Anti-Retroviral Therapy Study Group.CD4R count-guided interruption of antiretroviral treatment. N Engl JMed 2006; 355:2283–2296.21. Baker J, Peng G, Rapkin J, et al., Terry Beirn Community Programsfor Clinical Research on AIDS (CPCRA). CD4R count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS2008; 22:841–848.22. Mallal S, Phillips E, Carosi G, et al. PREDICT-1 Study Team. HLA-BM5701 screening for hypersensitivity to abacavir. N Engl J Med2008; 358:568–579.23. Sax P, Tierney C, Collier A, et al. ACTG 5202: shorter time to virologicfailure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine(TDF/FTC) as part of combination therapy in treatment-naivesubjects with screening HIV RNA ≥ 100,000 c/mL. In:Abstracts of the 17th — International AIDS Conference, 3–8 August2008, Mexico City, Mexico, Abstract THAB0303.